Relief Therapeutics (OTCMKTS:RLFTF) has been in focus among many investors for quite a while owing to its work with regards to aviptadil, which is meant for treating patients suffering from severe respiratory problems brought about by COVID 19 infection.
This morning, the company is expected to be in focus again among investors after it provided an update with regards to the product. The company revealed that recently it got scientific advice with regards to the product from the United Kingdom’s regulatory body Medicines and Healthcare Products Regulatory Agency (MHRA). The guidance was provided by the agency after at the time of a meeting that had taken place with the company.
The MHRA provided Relief Therapeutics with advice with regards to the pathway that it would need to take for a conditional marketing approval so that its product RLF-100 (aviptadil) could be administered intravenously. However, at the same time, it should be noted that the approval in question is dependent on the data that the company will need to furnish from the Phase 2b/3 study for the product that is being conducted by NeuroRx, its partner, in the United States. It remains to be seen if the Relief stock gets any action today.